Le Lézard
Classified in: Health, Science and technology
Subjects: CCA, TDS, TRI

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting


ROCKVILLE, Md., Jan. 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present data from the Phase II AAVIATE® trial of suprachoroidal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) at Hawaiian Eye and Retina 2024 Meeting being held January 13-19, 2024 in Maui, HI. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal conditions.

Title: Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: Results from the Phase II AAVIATE® study
Presenter: John D. Pitcher, III, M.D., Eye Associates of New Mexico
Date/Time: Tuesday, January 16, 2024, 2:47 p.m. EST

REGENXBIO will host a conference call Tuesday, January 16, 2024, at 4:30 p.m. EST with Dr. Pitcher and Allen Ho, M.D., FACS, FASRS, Co-Director, Wills Eye Retina Service and Director, Retina Research, to discuss these results and the ABBV-RGX-314 program.

Conference call details
Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A copy of the slides being presented will be available via the Company's investor website. Those who plan on participating are advised to join 15 minutes prior to the start time. A replay of the webcast will also be available via the Company's investor website approximately two hours after the call's conclusion.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack
Corporate Communications
[email protected] 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
[email protected]

(PRNewsfoto/REGENXBIO Inc.)

 

SOURCE REGENXBIO Inc.


These press releases may also interest you

at 15:33
FDA Roundup: May 17, 2024
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc.) for extensive stage small cell lung cancer...

at 15:27
Meditrina Announces 510(k) Clearance for Gen 2 Bipolar RF Hysteroscopy System and Aveta Glo Bipolar RF Device
Meditrina, a key leader in women's health medical devices, is thrilled to announce the FDA 510(k) clearance of its Gen 2 bipolar RF hysteroscopy system. This new system features bipolar radiofrequency technology, and a new bipolar RF device called...

at 15:25
JASON S. GOLDSTEIN OF PARKER WAICHMAN LLP NAMED TO PLAINTIFFS' STEERING COMMITTEE IN NATIONAL GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION
Jason S. Goldstein, Senior Litigation Counsel in the Mass Torts Department for the national law firm Parker Waichman LLP, was appointed to the Plaintiffs' Steering Committee ("PSC") in the multi-district litigation (MDL) involving injuries allegedly...

at 15:00
GLOBAL PORPHYRIA DAY IS MAY 18
United Porphyrias Association (UPA) is proud to announce May 18 as Global Porphyria Day. Global Porphyria Day is intended to create awareness that prompts action for improved healthcare, increased research, and enhanced support for individuals with...

at 14:53
Blue Shield of California Appoints Senior Executives to Accelerate Healthcare Transformation
Blue Shield of California today announced the appointment of two senior executives to help the nonprofit health plan accelerate its ambitious plans to transform the healthcare system and bolster its growth plans....

at 14:45
The Inner Circle Acknowledges, Anika Chowhan as a Most Trusted Healthcare Professional
Prominently featured in The Inner Circle, Anika Chowhan is acknowledged as a Most Trusted Healthcare Professional for her contributions to Pediatrics. Dr. Chowhan received a Bachelor of Arts degree at the University of Berkeley and earned a Medical...

More news about Health...


News published on and distributed by: